Top

Supportive Care in Cancer

Published in:

01-02-2017 | Original Article

Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study

Authors: Noor Al-Dasooqi, Joanne Bowen, Colin Bennett, John Finnie, Dorothy Keefe, Rachel Gibson

Published in: Supportive Care in Cancer | Issue 2/2017

Abstract

Purpose

Chemotherapy-induced mucositis is characterised by damage to mucous membranes throughout the alimentary tract. This study aims to investigate the expression of cell adhesion molecules (CAMs) following treatment with irinotecan.

Methods

Dark agouti rats received a single dose of 175 mg/kg irinotecan and sacrificed at various time points after treatment. Picro-sirius red staining indicated an increase in collagen around crypts from 24 h in both small and large intestinal regions and this diminished at the later time points. CAMs E-cadherin, P-selectin, E-selectin and integrin-α1 were examined using immunohistochemistry.

Results

E-cadherin was significantly elevated in jejunal crypts at the time of maximal tissue damage (48 h), while it decreased at the healing phase (96 h) in both jejunum and colon. P-selectin expression decreased significantly in the jejunum following irinotecan. Crypt expression of E-selectin was significantly elevated in the healing phase of mucositis (96 h). Integrin-α1 expression was significantly altered during the time course in the villus (p = 0.0032) and lamina propria (p = 0.039).

Conclusions

Irinotecan induced a significant alteration in CAM expression in the jejunum and colon. Changes in adhesion molecule expression may have a direct impact on the loss of mucosal layer integrity seen in mucositis.

Sonis S (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:s3–11

Gibson R, Bowen J, Cummins A, Keefe D (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188–195CrossRefPubMed

Yeoh A, Bowen J, Gibson R, Keefe D (2005) Nuclear factor κB (NFκB) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295–1303CrossRefPubMed

Sonis S (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277–284CrossRefPubMed

Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J, Migliorati C, McGuire D, Hutchins R, Peterson D (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed

Keefe D (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12:6–9CrossRefPubMed

Murphy B (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13–21PubMed

Sonis S (2004) A biological approach to mucositis. J Support Oncol 2:21–32PubMed

Logan R, Gibson R, Bowen J, Stringer A, Sonis S, Keefe D (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33–41CrossRefPubMed

10.

Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293–297CrossRefPubMed

11.

Stringer A, Gibson R, Bowen J, Ashton K, Logan R, Al-Dasooqi N, Yeoh A, Keefe D (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90:489–499CrossRefPubMedPubMedCentral

12.

Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, Keefe D (2009) Gastrointestinal microflora and mucins play a role in the development of 5-fluorouracil-induced gastrointestinal mucositis in rats. Exp Biol Med 234:430–441CrossRef

13.

Stringer A, Gibson R, Bowen J, Keefe D (2009) Chemotherapy-induced changes to microflora: evidence and implications of change. Curr Drug Metab 10:79–83CrossRefPubMed

14.

Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, Keefe D (2008) Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol Ther 7:1919–1925CrossRefPubMed

15.

Al-Dasooqi N, Bowen J, Gibson R, Logan R, Stringer A, Keefe D (2011) Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol 92:357–365CrossRefPubMedPubMedCentral

16.

Michael H, Gordon I, and Wojciech P (2003) Histology: a text and atlas. 4th edition ed. Lippincott Williams & Wilkins: Philadelphia, US

17.

Yurchenco P, Schittny J (1990) Molecular architecture of basement membranes. FASEB J 4:1577–1590PubMed

18.

Beaulieu J (1997) Extracellular matrix components and integrins in relationship to human intestinal epithelial cell differentiation. Prog Histochem Cytochem 31:1–78CrossRefPubMed

19.

Meredith J, Fazeli B, Schwartz M (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953–961CrossRefPubMedPubMedCentral

20.

Carroll K, Wong T, Drabik D, Chang E (1988) Differentiation of rat small intestinal epithelial cells by extracellular matrix. Am J Phys 254:g355–g360

21.

Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BG, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50(1):53–58CrossRefPubMed

22.

Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47(12):2751–2757CrossRefPubMed

23.

Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18(9):1095–1100CrossRefPubMed

24.

Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM (2007) Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 53(5):360–369CrossRefPubMed

25.

Logan R, Stringer A, Bowen J, Yeoh A, Gibson R, Sonis S, Keefe D (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33:448–460CrossRefPubMed

26.

Bowen J, Gibson R, Keefe D, Cummins A (2005) Cytotoxic chemotherapy up-regulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56–62CrossRefPubMed

27.

Gibson R, Bowen J, Inglis M, Cummins A, Keefe D (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095–1100CrossRefPubMed

28.

Ma M, McLeod H (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–49CrossRefPubMed

29.

Gibson R, Bowen J, Alvarez E, Finnie J, Keefe D (2007) Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 53:360–369CrossRefPubMed

30.

Potten C, Booth C, Pritchard D (1997) The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol 78:219–243CrossRefPubMedPubMedCentral

31.

Orberg J, Klein L, Hiltner A (1982) Scanning electron microscopy of collagen fibers in intestine. Connect Tissue Res 9:187–193CrossRefPubMed

32.

Lalla R, Bowen J, Barasch A, Elting L, Epstein J, Keefe D, McGuire D, Nicolatou-Galitis O, Peterson D, Raber-Durlacher J, Sonis S, Elad S, (MASCC/ISOO) TMGLGotMAoSCiCaISoOO (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461CrossRefPubMedPubMedCentral

33.

Bruewer M, Luegering A, Kucharzik T, Parkos C, Madara J, Hopkins A, Nusrat A (2003) Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171:6164–6172CrossRefPubMed

34.

Wardill H, Bowen J, and Gibson R (2013) Irinotecan disrupts tight junction protein occludin in the rat small intestine in Multinational Association for Supportive Care in Cancer. Journal of Supportive Care in Cancer: Berlin, Germany

35.

Walzog B, Gaehtgens P (2000) Adhesion molecules: the path to a new understanding of acute inflammation. Physiology 15:107–113

Title: Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study
Authors: Noor Al-Dasooqi
Joanne Bowen
Colin Bennett
John Finnie
Dorothy Keefe
Rachel Gibson
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3413-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

Risk factors for same-admission mortality after pathologic fracture secondary to metastatic cancer

The use of opioids in cancer patients with renal impairment—a systematic review

A qualitative exploration of oncology nurses’ family assessment practices in Denmark and Australia

Photobiomodulation therapy in the management of chronic oral graft-versus-host disease

Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer